Flexion Enters Into Agreements With Four Pharma Majors
The agreements with AstraZeneca, Merck Serono (a division of Merck KGaA, Germany) and one other partner establish for Flexion, a mature pipeline of clinically enabled drug candidates focused
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.